Expert Interview
Discussing the Recent FDA Approval of Amneal Pharmaceuticals' Self-Administered Drug, Brekiya, for the Treatment of Acute Cases of Migraine and Severe Cluster Headaches in Adults
Ticker(s): AMRXInstitution: Mount Sinai
- Emeritus Director of Headache and Pain Medicine and Professor of Neurology, Anesthesiology and Rehabilitation at Icahn school of Medicine
- President of the World Headache Society
- One of the founding editors of CEPHALAGIA, the international headache journal. Also served as associate editor of HEADACHE, the journal of the American Headache Society
Where are the unmet needs in acute migraine and cluster headache treatment?
Added By: nick_adminWhat is your initial impression of Brekiya (dihydroergotamine mesylate autoinjector) following FDA approval?
Added By: nick_adminWhere in the treatment algorithm do you see Brekiya being used?
Added By: nick_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
